Alstead E M, Ryan F P, Holdsworth C D, Ashton M G, Moore M
Gut. 1983 May;24(5):418-20. doi: 10.1136/gut.24.5.418.
Prophylactic maintenance therapy for one year using ranitidine 150 mg at night or a placebo was assessed in 68 patients whose gastric or duodenal ulcers had previously healed after therapy with ranitidine 150 mg twice daily or placebo. Gastroscopy was carried out on symptomatic relapse and at the end of the year. Of the duodenal ulcer group, seven out of 20 relapsed on ranitidine compared with 15 out of 17 on placebo (p less than 0.001). Of the gastric ulcer group one of 15 patients relapsed on ranitidine compared with 11 of 16 patients on placebo (p less than 0.005). There were no adverse effects from ranitidine during the trial period. Ranitidine in low dose maintenance therapy is therefore reasonably effective in the prevention of relapse of duodenal ulcers and appears to be particularly effective in preventing relapse of gastric ulcers at least for one year. As gastric ulcers occur more frequently in the older patients in whom there are often medical contraindications to surgery, maintenance treatment may be appropriate for many such patients.
对68例曾接受每日2次150毫克雷尼替丁治疗或安慰剂治疗后胃溃疡或十二指肠溃疡已愈合的患者，评估了使用每晚150毫克雷尼替丁或安慰剂进行为期一年的预防性维持治疗的效果。在出现症状复发时以及一年结束时进行胃镜检查。十二指肠溃疡组中，20例接受雷尼替丁治疗的患者中有7例复发，而17例接受安慰剂治疗的患者中有15例复发（p<0.001）。胃溃疡组中，15例接受雷尼替丁治疗的患者中有1例复发，而16例接受安慰剂治疗的患者中有11例复发（p<0.005）。在试验期间雷尼替丁未出现不良反应。因此，低剂量雷尼替丁维持治疗在预防十二指肠溃疡复发方面相当有效，并且至少在一年内预防胃溃疡复发似乎特别有效。由于胃溃疡在老年患者中更常见，而这些患者往往存在手术的医学禁忌证，维持治疗可能适用于许多此类患者。
